Summer 2026
Posted on 10/3/2025
Global consulting delivering economic, litigation analysis
No salary listed
London, UK + 1 more
More locations: Cambridge, UK
Hybrid
3–4 days per week in-office; occasional remote work during holidays.
CRA is a global consulting firm that offers specialized services in litigation, regulatory, financial, and management consulting. It uses economic and financial analysis, modeling, and expert testimony to support clients in disputes, regulatory matters, and strategic decisions. The firm differentiates itself through rigorous quantitative analysis, industry expertise, and a worldwide network that delivers tailored, objective insights. Its goal is to help clients achieve favorable outcomes by providing precise analyses, clear testimony, and practical recommendations.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
City of Brussels, Belgium
Founded
1978
Help us improve and share your feedback! Did you find this helpful?
Wellness Program
Flexible Work Hours
Remote Work Options
Professional Development Budget
Charles River Associates has announced that Director Christine Detrick will become Lead Independent Director, effective 16th July 2026, following the planned retirement of current Lead Independent Director William Concannon. Concannon's retirement will take effect at CRA's 2026 Annual Meeting of Shareholders. Concannon has served on CRA's board since 2000 and as Lead Director since 2020. He informed the board of his decision to retire to spend more time with family. Detrick has been a board member since 2020 and currently chairs the Nominating and Corporate Governance Committee. CRA is a global consulting firm specialising in economic, financial and management consulting services, headquartered in Boston with offices worldwide.
Invest in European pharma to reap dividends, report says. 17 March 2026 The European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the findings from a report by consultants Charles River Associates (Nasdaq: CRAI) that the trade group had commissioned. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK 16 March 2026 9 March 2026 16 February 2026 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news 17 March 2026 Company spotlight. A private biotechnology company developing synthetic macrocyclic peptide therapeutics designed to target historically "undruggable" proteins. Unnatural Products focuses on bridging the gap between small molecules and biologics through orally available, cell-permeable macrocycles. More features in pharmaceutical. 17 March 2026
CRA International has raised its 2026 revenue guidance to $785 million to $805 million in constant currency, signalling expectations for higher consulting demand. The company reported fourth-quarter 2025 revenue of $196.96 million and full-year 2025 revenue of $751.58 million, with net income of $54.78 million. The firm declared a quarterly dividend of $0.57 per share, payable on 20 March 2026. This marks continued cash returns to shareholders despite net debt of approximately $100.6 million. CRA's investment narrative remains tied to consulting demand driven by global mergers and acquisitions and regulatory activity. The key risk is demand cyclicality, particularly if dealmaking or enforcement activity slows sharply. Community fair value estimates for the stock range from $252 to $333 per share.
Charles River Associates has appointed Dr Steven Tadelis, a professor at UC Berkeley's Haas School of Business, as a senior consultant to its Antitrust & Competition Economics Practice. Dr Tadelis specialises in e-commerce and internet economics, with research covering digital advertising effectiveness, online marketplace reputation systems and algorithmic pricing. Dr Tadelis has provided expert economic testimony in major US and Canadian litigation cases involving digital markets and participated in Federal Trade Commission hearings. He previously held senior roles at eBay Research Labs and Amazon, serving as vice president of economics and market design. The appointment strengthens CRA's testifying capabilities in antitrust and consumer protection cases involving digital platforms and internet economics.
Charles River Associates reported fourth-quarter revenue of $196.96 million, beating consensus estimates of $190.54 million, though earnings per share of $2.06 fell slightly short of the $2.07 consensus. The company achieved its eighth consecutive year of record annual revenue. Revenue grew 11.6% year-over-year in the fourth quarter, driven by double-digit growth in four practices: Antitrust & Competition Economics, Energy, Forensic Services, and Labor & Employment. Life Sciences and Risk, Investigations & Analytics also expanded. Geographically, North American operations increased 9.4% whilst international operations grew 21.9%. CEO Paul Maleh said strong top-line growth drove record profitability, with net income, earnings per diluted share and EBITDA each reaching new annual highs.